Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) — Onconetix, Inc., (Nasdaq:BWV) (“Onconetix” or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell.
Related news for (BWV)
- Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
- Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
- Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
- Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company